Progressive multifocal leukoencephalopathy in patients with multiple sclerosis

Current Opinion in Neurology

Volumn 26, Issue 3, 2013, Pages 318-323

  Baldwin, Kelly J ^a,b   Hogg, Jeffery P ^a,b  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

JC virus; multiple sclerosis; natalizumab; progressive multifocal leukoencephalopathy

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN G; MEFLOQUINE; METHOTREXATE; MIRTAZAPINE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; VIRUS ANTIBODY;

APHASIA; BRAIN BIOPSY; CELLULAR IMMUNITY; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; CONTRAST ENHANCEMENT; CORTICOSTEROID THERAPY; DEMYELINATION; DIFFERENTIAL DIAGNOSIS; DISABILITY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG WITHDRAWAL; FATALITY; HEMIANOPIA; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOSUPPRESSIVE TREATMENT; JC VIRUS; MULTIPLE SCLEROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; PATIENT PREFERENCE; PATIENT SELECTION; PLASMAPHERESIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; RISK ASSESSMENT; SEIZURE; TREATMENT DURATION; VIRUS ENTRY; VIRUS LOAD;

ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; JC VIRUS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MULTIPLE SCLEROSIS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84877706482     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e328360279f     Document Type: Review

References (19)

1. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999; 122:871-882. (Pubitemid 29219261)
2. Rudick RA. Multiple sclerosis, natalizumab, and PML: helping patients decide. Cleve Clin J Med 2011; 78 (Suppl 2):S18-23.
3. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354:899-910.
4. O'Connor PW, Goodman A, Kappos L, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 2011; 76:1858-1865.
5. Astrom KE, Mancall EL, Richardson EP. Progressive multifocal leukoencephalopathy: a hitherto unrecognized complication of chronic lymphocytic leukemia and lymphoma. Brain 1958; 81:99-111.
6. Padgett BL, ZuRhein GM, Walker DL, et al. Cultivation of papova-like virus from human brain with progressive multifocal leukoencephalopathy. Lancet 1971; 1:1257-1260.
7. Berger JR. The basis for modeling progressive multifocal leukoencephalopathy pathogenesis. Curr Opin Neurol 2011; 24:262-267.
8. Gan Y, Liu R, Wu W, et al. Antibody to a4 integrin suppresses natural killer cells infiltration in central nervous system in experimental autoimmune encephalomyelitis. J Neuroimmunol 2012; 247:9-15.
9. Biogen Idec communication: PML incidence in patients receiving TYSABRI (natalizumab); 2012. http://www.biogenidec.com/therapies.aspx? ID5489.
10. Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 2010; 68:295-303.
11. Fox R. Advances in the management of PML: focus on natalizumab. Cleve Clin J Med 2011; 78 (Suppl 2):S33-S37.
12. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab- associated progressive multifocal leukoencephalopathy. N Engl J Med 2012; 366: 1870-1880.
13. Fox RJ, Rudick RA. Risk stratification and patient counseling for natalizumab in multiple sclerosis. Neurology 2012; 78:436-437.
14. Clifford DB, De Luca A, Simpson DM, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010; 9:438-446.
15. Kuhle J, Gosert R, Bü hler R, et al. Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS. Neurology 2011; 77:2010-2016.
16. Phan-Ba R, Lommers E, Tshibanda L, et al. MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy. J Neurol Neurosurg Psychiatry 2012; 83:224-226.
17. Sahraian MA, Radue EW, Eshaghi A, et al. Progressive multifocal leukoencephalopathy: a review of the neuroimaging features and differential diagnosis. Eur J Neurol 2012; 19:1060-1069.
18. Khatri BO. Therapeutic plasma exchange for worsening multiple sclerosis: does it work? Expert Rev Clin Immunol 2009; 5:491-493.
19. Brickelmaier M, Lugovskoy A, Kartikeyan R, et al. Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob Agents Chemother 2009; 53:1840-1849.